-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK says BEHOLD-1 trial shows 62% response in platinum-resistant ovarian cancer

PUBT·04/12/2026 14:28:59
Listen to the news
GSK says BEHOLD-1 trial shows 62% response in platinum-resistant ovarian cancer
  • GSK reported positive early-stage BEHOLD-1 results for mocertatug rezetecan, an antibody-drug conjugate targeting B7-H4 in gynecologic cancers.
  • Data were scheduled for first presentation in a late-breaking oral session at Society of Gynecologic Oncology annual meeting in San Juan, Puerto Rico.
  • Study showed meaningful tumor shrinkage in platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer, conditions with limited effective options.
  • Safety profile was described as manageable, supporting continued development.
  • Program advanced into five global Phase III trials planned for 2026, including earlier-line settings in ovarian and endometrial cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on April 12, 2026, and is solely responsible for the information contained therein.